Vyleesi and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

The direct answer

There is no established pharmacokinetic interaction between bremelanotide and gabapentin. Neither drug is metabolized through cytochrome P450 enzymes, so one is not expected to raise or lower blood levels of the other. The clinically relevant concern is additive side-effect burden, chiefly nausea, dizziness, and sedation, plus the fact that both drugs depend partly or entirely on renal clearance, which matters more in patients with reduced kidney function. Combining the two is not flagged as dangerous in FDA labeling for either drug, but it has not been specifically studied as a pair, so caution rests on pharmacologic reasoning rather than a dedicated interaction trial.

Who this applies to and why the overlap is realistic

Bremelanotide (brand name Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, delivered as a self-injected 1.75 mg subcutaneous dose used as needed, up to a labeled maximum frequency. Gabapentin is FDA-approved for certain seizure disorders and postherpetic neuralgia, and is widely prescribed off-label for chronic pain, restless legs syndrome, and anxiety-adjacent symptoms. Women with chronic pain or neurologic conditions who take gabapentin can also have HSDD, so the two drugs are plausibly co-prescribed in real practice even though no dedicated interaction study appears to exist for this pair.

What is pharmacologically established

Bremelanotide is a cyclic peptide that is not a substrate, inhibitor, or inducer of the major CYP450 enzymes, according to its FDA prescribing information. Gabapentin is not hepatically metabolized at all; it is excreted unchanged by the kidneys. Because neither drug depends on CYP450 metabolism, a metabolic interaction where one drug raises or lowers the other's blood level through liver enzymes is not expected. This is the strongest, most citable fact on this page: bremelanotide and gabapentin have no known CYP450-mediated pharmacokinetic interaction, but both are renally cleared to some degree, and both list nausea, dizziness, and somnolence as adverse effects in their FDA labeling, so overlapping side effects rather than altered drug levels are the relevant clinical concern (FDA prescribing information for Vyleesi and Neurontin/gabapentin).

Renal clearance is where the two drugs converge. Gabapentin is essentially 100% dependent on the kidneys for elimination, and its FDA label requires dose reduction at each stage of declining kidney function. Bremelanotide's label also describes reduced clearance in renal impairment, though the exact magnitude of that change and whether it is clinically meaningful at typical HSDD dosing is a detail that should be verified directly against the current label rather than repeated from a secondary summary. In practice, a patient with reduced kidney function taking gabapentin already needs a dose adjustment under gabapentin's own label, independent of bremelanotide use; adding bremelanotide does not change that gabapentin renal-dosing requirement.

What is pharmacologically plausible but not proven together

Both drugs list dizziness, nausea, and somnolence among their common adverse effects in their respective FDA labels. It is pharmacologically plausible that using them on the same day increases the combined burden of these effects, since both act on the central nervous system through different receptor systems (gabapentin through voltage-gated calcium channel modulation, bremelanotide through melanocortin-4 receptor activation). However, no published trial has specifically tested bremelanotide plus gabapentin together, so the "additive" effect described here is an inference from each drug's individual label, not a measured finding. Readers should not treat specific combined-incidence numbers (for example, "nausea occurs in X% of patients taking both") as established, because that number has not been directly studied.

The idea that separating doses by one to two hours meaningfully reduces overlapping peak side effects is a reasonable pharmacokinetic-timing strategy but is not itself validated by a trial in this drug pair. It is a plausible, low-risk suggestion, not a guideline recommendation.

What is not established

There is no FDA boxed warning, contraindication, or specific dose-adjustment instruction for using bremelanotide and gabapentin together. Major interaction checkers do not carry a dedicated monograph for this specific pair, which more likely reflects an absence of data than a confirmed absence of risk. Claims about an exact quantified increase in nausea or dizziness when the two are combined, or an exact percentage change in bremelanotide exposure in renal impairment, should not be treated as verified until checked against the current FDA label text, since those specific figures could not be confirmed from the sources available for this review.

Bremelanotide's label does describe a documented interaction with naltrexone (an opioid antagonist), where bremelanotide reduces naltrexone exposure. That is a distinct, labeled interaction and is not evidence about gabapentin; it should not be extrapolated to other drugs.

The one interaction pathway with a clearer signal: opioids plus gabapentin

The FDA issued a drug safety communication warning that gabapentin and pregabalin, when combined with opioids or other central nervous system depressants, are associated with serious breathing problems, including in patients without other risk factors (FDA Drug Safety Communication, December 2019). Gabapentin's own label carries a boxed warning about respiratory depression risk with concomitant CNS depressants. Bremelanotide is not an opioid or a classic CNS depressant, but a patient taking gabapentin plus an opioid who also starts bremelanotide is adding a third agent with CNS side effects (dizziness, somnolence) to an already flagged combination. This three-drug scenario, gabapentin plus opioid plus bremelanotide, deserves more attention from a prescriber than the two-drug bremelanotide-gabapentin question alone.

Practical monitoring and counseling points

These points follow from each drug's individual labeling rather than from a study of the combination:

• Ask about all CNS-active medications, including opioids, benzodiazepines, and sedating antihistamines, before starting bremelanotide in a patient on gabapentin.
• Check baseline kidney function (creatinine, eGFR) in patients with known or suspected renal impairment, since gabapentin dosing must already be adjusted below an eGFR of 60 mL/min per its label, and reduced renal clearance can plausibly affect bremelanotide handling as well.
• Advise patients not to drive or operate machinery on days they use both drugs until they know how the combination affects them, given that dizziness and somnolence appear on both labels.
• Recommend a light meal before bremelanotide injection, per general product guidance, to help with nausea tolerability.
• Tell patients to report prolonged flushing, nausea, or dizziness lasting several hours, and to seek urgent care for chest pain, fainting, or signs of severe allergic reaction, which are not expected effects of either drug alone.
• Bremelanotide's labeled maximum use frequency limits how often the two drugs can overlap in the first place; using it less often than the maximum reduces cumulative overlap exposure.

None of this constitutes an individualized dosing recommendation. A prescriber or pharmacist familiar with the patient's full medication list and renal function should make the final call on co-administration and any dose timing.

Evidence-status interaction assessment

Evidence boundary

What is established: neither drug relies on CYP450 metabolism, so a classic metabolic drug interaction is not expected. Both drugs independently list nausea, dizziness, and somnolence as adverse effects, and gabapentin's dosing must already be reduced in renal impairment regardless of bremelanotide use. What is plausible but unproven: that using both drugs together measurably increases combined side-effect frequency, and that dose-timing separation meaningfully reduces that overlap. What is not established: any FDA-recognized interaction warning specific to this pair, and any precise quantified change in bremelanotide exposure from renal impairment or from gabapentin co-administration. Readers and clinicians should treat this page as a reasoning framework built from each drug's individual labeling, not as evidence of a studied bremelanotide-gabapentin interaction trial.

When to seek urgent care

Severe or persistent dizziness with fainting, chest pain, difficulty breathing, or signs of a severe allergic reaction (swelling of the face or throat, hives, trouble breathing) are not expected effects of either drug and warrant emergency evaluation rather than home monitoring. Gradually worsening drowsiness in a patient also taking an opioid or another sedating medication should prompt contact with the prescriber promptly given the FDA's warning about combined respiratory depression risk with gabapentinoids and CNS depressants.